Using Paclitaxel Schedules as Adjuvant Therapy for Breast Cancer
Andrew D. Seidman, MD, comments on the findings of the phase III S0221 trial, which compared two schedules of paclitaxel as adjuvant therapy for breast cancer.
Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, comments on the findings of the phase III S0221 trial, which compared two schedules of paclitaxel as adjuvant therapy for breast cancer.
Seidman says that he uses the dose-dense paclitaxel regimen given every two weeks in his practice. This regimen does lend itself to the injection of a growth factor to stimulate white blood cell recovery. This injection has a significant cost and toxicity profile, Seidman says.
Clinical Pearls
The trial found that either the dose-dense paclitaxel administered every two weeks or weekly paclitaxel given over 12 weeks is acceptable.
- Dose-dense paclitaxel (every two weeks) requires the injection of a growth factor to stimulate white blood cell recovery, which has a significant cost and toxicity profile
- The phase III S0221 trial found that either dose-dense paclitaxel administered every two weeks or weekly paclitaxel given over 12 weeks is acceptable
<<<
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
